Yet, compared to erlotinib alone, patients with high E-cadherin levels at recruitment had a longer OS [71] Ramalingam et al. involved 94 patients with advanced NSCLC in a randomly selected, double-blind, placebo-controlled phase II trial evaluating cisplatin/paclitaxel combined with vorinostat or a placebo. The gene discussed is CDH1; the disease is non-small cell lung carcinoma.